RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
European Society of Cardiology Committee for Practice
Guidelines and Policy Conferences (Committee to Develop
Guidelines for the Management of Patients With Atrial
Fibrillation): developed in Collaboration With the North
American Society of Pacing and Electrophysiology. J
Am.Coll.Cardiol. 38:1231-1266, 2001.
1102. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R,
Charbonnier B, y cols. Expert consensus document on the
use of antiplatelet agents. The task force on the use of antiplatelet
agents in patients with atherosclerotic cardiovascular
disease of the European society of cardiology. Eur.Heart
J. 25:166-181, 2004.
1103. TDRS Investigators. Aspirin effects on mortality and morbidity
in patients with diabetes mellitus. Early treatment diabetic
retinopaty study report 14. JAMA 268, 1292-1300. 1992.
1104. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen
S, Omblus R: Double-blind trial of aspirin in primary prevention
of myocardial infarction in patients with stable chronic
angina pectoris. The Swedish Angina Pectoris Aspirin Trial
(SAPAT) Group. Lancet 340:1421-1425, 1992.
1105. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA,
Berger P: Antithrombotic therapy in patients undergoing percutaneous
coronary intervention. Chest 119:321S-336S,
2001.
1106. The GUSTO IV-ACS investigators. Effect of glycoprotein
IIb/IIIa receptor blocker acbiximab on outcome in patients
with acute coronary syndromes without early coronary
revascularisation: the GUSTO IV-ACS randomised trial.
Lancet , 1915-1924. 2001.
1107. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones
AA, y cols. Randomized, placebo-controlled trial of platelet
glycoprotein IIb/IIIa blockade with primary angioplasty for
acute myocardial infarction. ReoPro and Primary PTCA
Organization and Randomized Trial (RAPPORT)
Investigators. Circulation 98:734-741, 1998.
1108. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M,
Mehilli J, y cols. Effect of glycoprotein IIb/IIIa receptor blockade
with abciximab on clinical and angiographic restenosis
rate after the placement of coronary stents following
acute myocardial infarction. J Am.Coll.Cardiol. 35:915-921,
2000.
1109. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin
JJ, Gy cols. Comparison of angioplasty with stenting, with or
without abciximab, in acute myocardial infarction. N Engl J
Med. 346:957-966, 2002.
1110. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad
S, Villain P, y cols. Platelet glycoprotein IIb/IIIa inhibition
with coronary stenting for acute myocardial infarction. New
England Journal of Medicine 344:1895-1903, 2001.
1111. Stein PD, Dalen JE, Goldman S, Theroux P: Antithrombotic
therapy in patients with saphenous vein and internal mammary
artery bypass grafts. Chest 119:278S-282S, 2001.
1112. Jackson MR, Clagett GP: Antithrombotic therapy in peripheral
arterial occlusive disease. Chest 119:283S-299S, 2001.
1113. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye
RL, y cols. ACC/AHA/ESC guidelines for the management of
patients with atrial fibrillation. A report of the American
College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines and Policy
Conferences (Committee to develop guidelines for the
management of patients with atrial fibrillation) developed in
collaboration with the North American Society of Pacing and
Electrophysiology. Eur.Heart J 22:1852-1923, 2001.
1114. Salem DN, Daudelin HD, Levine HJ, Pauker SG, Eckman
MH, Riff J: Antithrombotic therapy in valvular heart disease.
Chest 119:207S-219S, 2001.
1115. Guyatt G, Schunemann H, Cook D, Jaeschke R, Pauker S,
Bucher H: Grades of recommendation for antithrombotic
agents. Chest 119:3S-7S, 2001.
1116. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ,
DeMarco S, Tournier B, y cols. Cyclooxygenase inhibitors
and the antiplatelet effects of aspirin. N Engl J Med.
345:1809-1817, 2001.
1117. Januzzi JL, Jr. Snapinn SM, DiBattiste PM, Jang IK, Theroux P:
Benefits and safety of tirofiban among acute coronary
syndrome patients with mild to moderate renal insufficiency:
results from the Platelet Receptor Inhibition in Ischemic
Syndrome Management in Patients Limited by Unstable
Signs and Symptoms (PRISM-PLUS) trial. Circulation
105:2361-2366, 2002.
1118. Jardine AG, McLaughlin. Cardiovascular complications of
renal disease. Heart 86: 459-466, 2001.
1119. Baigent C, Burbury K, Wheeler D. Premature cardiovascular
disease in chronic renal failure. Lancet 356:147-52,2000.
1120. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in
dialysis patients.Semin Dial 12:69-76,1999.
1121. Informe preliminar de diálisis y trasplante año 2002 de la
Sociedad Española de Nefrología. Congreso Nacional de la
Sociedad Española de Nefrología. Palma de Mallorca (2003).
1122. U.S Renal Data System: USRDS 2002/2000 Annual Data
Report. Bethesda MD, National Institutes of Health, National
Institute of Diabetes an Digestive and Kidney Diseases 2002
/2000
1123. Rostand SG. Coronary heart disease in chronic renal insufficiency:
some management considerations. J Am Soc
Nephrol 11:1948-1956,2000.
1124. Gheorghiade M, Bonow RO. Chronic heart failure in the
United States: A manifestation of coronary artery disease.
Circulaton 97:282-289, 1998.
1125. Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary
artery disease prior to initiation of haemodialysis in
patients with end-stage renal disease. Nephrol Dial
Transplant 12:718-723, 1997.
1126. Sarnak MK. Cardiovascular complications in chronic kidney
disease. Am J Kidney Dis 41(Suppl 5):11-17, 2003
1127. Schunkert H, Hense HW. A heart price to pay for anaemia.
Nephrol Dial Transplant 16:445-448, 2001.
1128. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic
heart disease: Insignts from coronary angiography.
Kidney Int 25:653-659, 1984.
1129. Schwarz U, Buzello M, Ritz , Stein G, Raabe G, Wiest G y
cols. Morphology of coronary atherosclerotic lesions inpatients
with end-stage renal failure. Nephrol Dial Transplant
17:218-23, 2000.
1130. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H.
Arterial structure and function in end-stage renal disease.
Nephrol Dial Transplant 17:1713-1724, 2002.
1131. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato
JA, Szczech LA y cols. Association between pulse pressure
and mortality in patients undergoing maintenance hemodialysis.
JAMA 287:1548-1555, 2002.
221